Impact of an intern-supported antiviral stewardship program for cytomegalovirus prophylaxis and management in high-risk abdominal solid organ transplant recipients

被引:0
作者
Mahn, Lindsey [1 ]
Chandran, Mary Moss [1 ]
Doligalski, Christina Teeter [1 ]
Chargualaf, Laura Mincemoyer [1 ]
机构
[1] Univ North Carolina Chapel Hill, Med Ctr, Chapel Hill, NC USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2025年 / 8卷 / 01期
关键词
CMV; pharmacy intern; solid organ transplant; stewardship; INFECTION; VALGANCICLOVIR; DISEASE; PREVENTION; GUIDELINES;
D O I
10.1002/jac5.2061
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionCytomegalovirus (CMV) infection is associated with increased graft loss and mortality after solid organ transplantation (SOT). CMV infection risk is highest among seronegative recipients of seropositive donors (D+/R-). Careful monitoring is imperative to ensure appropriate care.ObjectivesThis study investigates the impact of intern-supported pharmacist-driven monitoring on CMV outcomes in D+/R- abdominal SOT recipients.MethodsA single-center retrospective cohort study was conducted in CMV D+/R- abdominal SOT recipients transplanted between August 1, 2021, and July 31, 2023 to compare recipients undergoing pharmacy intern review versus standard monitoring. A pharmacy student intern reviewed a list of recipients maintained in the electronic health record weekly to ensure proper CMV prophylaxis and management. Following institutional protocols, the intern identified and recommended interventions to the pharmacists for implementation. Primary outcomes included the incidence of CMV infection within 9 months posttransplant and time to CMV eradication after infection. Secondary outcomes included the incidence of antiviral resistance, viral breakthrough, allograft loss, and recipient death.Results69 D+/R- SOT recipients were included (36 control, 33 intervention). Baseline demographics were similar. There was a nonsignificant decrease in CMV infection within 9 months posttransplant in the intervention group. However, the mean time to CMV eradication after infection was significantly shorter in the intervention group (63 days vs. 24 days, p = 0.004). No differences in secondary outcomes were observed.ConclusionsCMV infection rates remained elevated in D+/R- SOT recipients after transplant despite frequent reviews of prophylaxis and laboratory monitoring, which is likely a result of seronegative status and global immunosuppression. However, eradication of CMV infection can be significantly impacted by close monitoring, such as that provided by a pharmacy student intern, to reduce the time of active infection. This dramatic reduction in time to eradication has the potential to reduce the risk for negative allograft and recipient outcomes associated with CMV infection.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 46 条
  • [21] Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
    Khurana, Mark P.
    Lodding, Isabelle P.
    Mocroft, Amanda
    Sorensen, Soren S.
    Perch, Michael
    Rasmussen, Allan
    Gustafsson, Finn
    Lundgren, Jens D.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (06):
  • [22] Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial
    Manuel, Oriol
    Laager, Mirjam
    Hirzel, Cedric
    Neofytos, Dionysios
    Walti, Laura N.
    Hoenger, Gideon
    Binet, Isabelle
    Schnyder, Aurelia
    Stampf, Susanne
    Koller, Michael
    Mombelli, Matteo
    Kim, Min Jeong
    Hoffmann, Matthias
    Koenig, Katrin
    Hess, Christoph
    Burgener, Anne-Valerie
    Cippa, Pietro E.
    Huebel, Kerstin
    Mueller, Thomas F.
    Sidler, Daniel
    Dahdal, Suzan
    Suter-Riniker, Franziska
    Villard, Jean
    Zbinden, Andrea
    Pantaleo, Giuseppe
    Semmo, Nasser
    Hadaya, Karine
    Enriquez, Natalia
    Meylan, Pascal R.
    Froissart, Marc
    Golshayan, Dela
    Fehr, Thomas
    Huynh-Do, Uyen
    Pascual, Manuel
    van Delden, Christian
    Hirsch, Hans H.
    Jueni, Peter
    Mueller, Nicolas J.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (02) : 312 - 323
  • [23] Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis
    Akalin, E
    Sehgal, V
    Ames, S
    Hossain, S
    Daly, L
    Barbara, M
    Bromberg, JS
    AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) : 731 - 735
  • [24] Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients
    Imlay, Hannah
    Dumitriu Carcoana, Allison O.
    Fisher, Cynthia E.
    Wong, Beatrice
    Rakita, Robert M.
    Fishbein, Daniel P.
    Limaye, Ajit P.
    TRANSPLANT INFECTIOUS DISEASE, 2020, 22 (03)
  • [25] Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients
    Albatati, Sawsan
    Sharma, Atul
    Haubrich, Kathryn
    Wright, Alissa
    Gantt, Soren
    Blydt-Hansen, Tom D.
    PEDIATRIC RESEARCH, 2020, 87 (05) : 892 - 896
  • [26] Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease
    Belga, Sara
    Hernandez, Cristina
    Kabbani, Dima
    Cervera, Carlos
    TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (02)
  • [27] Increased Incidence of Cytomegalovirus Infection in High-Risk Liver Transplant Recipients Receiving Valganciclovir Prophylaxis Versus Ganciclovir Prophylaxis
    Shiley, Kevin T.
    Gasink, Leanne B.
    Barton, Todd D.
    Pfeiffenberger, Patrice
    Olthoff, Kim M.
    Blumberg, Emily A.
    LIVER TRANSPLANTATION, 2009, 15 (08) : 963 - 967
  • [28] Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
    Bodro, Marta
    Sabe, Nuria
    Llado, Laura
    Baliellas, Carme
    Niubo, Jordi
    Castellote, Jose
    Fabregat, Joan
    Rafecas, Antoni
    Carratala, Jordi
    LIVER TRANSPLANTATION, 2012, 18 (09) : 1093 - 1099
  • [29] Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis
    Limaye, Ajit P.
    Green, Margaret L.
    Edmison, Bradley C.
    Stevens-Ayers, Terry
    Chatterton-Kirchmeier, Sam
    Geballe, Adam P.
    Singh, Nina
    Boeckh, Michael
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (05) : 752 - 760
  • [30] Unraveling the Biologic Basis of Late-Onset Cytomegalovirus Disease in High-Risk Organ Transplant Recipients
    Singh, Nina
    TRANSPLANTATION, 2011, 91 (08) : 825 - 826